Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Phase

Condition

Ocular Hypertension

Glaucoma

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT03257813

SOPH122-0914/III

Ages > 18
All Genders

Study Summary

Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle glaucoma or ocular hypertension.

Study design: a multicentric, prospective, crossover (2x2), double blind clinical study. Sample size: one hundred patients with primary open angle glaucoma or ocular hypertension. Patients in the period 1: In the first sequence 30 patients will be assigned to receive the ophthalmic solution: Krytantek Ofteno ® (timolol 0.5%%/brimonidine 0.2%/dorzolamide 2%) 1 drop B.I.D. during 30 days and the second sequence 30 patients will be assigned to receive the ophthalmic solution: PRO-122 1 drop B.I.D. during 30 days in the same period. Washout period: 20 hours. Patients in the period 2: the pharmacological intervention change to the opposite therapy for 30 days

Eligibility Criteria

Inclusion

Inclusion Criteria:

18 years of age or older
male or female.
obtained in the external consultation.
With diagnosis primary of open-angle glaucoma and / or hypertension classified asmild, moderate or severe glaucomatous damage, users of Krytantek Ofteno® at least twomonths prior to inclusion and under control of the target IOP.
informed consent.

Exclusion

Exclusion Criteria: General Criteria

Subjects with topical or systemic medication that interferes decisively in the resultsof the study. (Such as topical immunomodulators, lacrimal point tamponade,corticosteroids, ocular hypotensives other than those listed above, artificial tearswith preservative).
Subjects (female) with an active sex life who are not using a contraceptive method.
Female Subjects in pregnancy or breastfeeding.
Female subjects with positive urine pregnancy test.
Positive drug addiction (verbal interrogation).
Subjects who have participated in any clinical research study in the last 40 days.
Legally or mentally disabled subjects to give informed consent for their participationin this study.
Subjects who can not comply with the appointments or with all the requirements of theprotocol. Ophthalmologic criteria
Subject with only one eye with vision.
Subjects with visual capacity 20/200 or worse.
Subjects with a narrow-angle history without treatment, with or without total orpartial closure of the angle in either eye.
Subjects with corneal abnormalities that prevent applanation tonometry.
Subjects with ocular surgery or ocular trauma 6 months prior to inclusion.
Any ocular laser surgery 3 months prior.
Any uncontrolled or progressive retinal disease.
Inflammatory diseases of any kind.
Contact lens wearers.
Subjects with a history of hypersensitivity to any of the ingredients of the researchproduct or its analogues.

Study Design

April 01, 2016

June 18, 2017

Study Description

The American Academy of Ophthalmology Glaucoma Panel: The primary open angle glaucoma (POAG) is a progressive, chronic optic neuropathy in adults in which intraocular pressure (IOP) and other currently unknown factors contribute to damage and in which, in the absence of other identifiable causes, there is a characteristic acquired atrophy of the optic nerve and loss of retinal ganglion cells and their axons. This condition is associated with an anterior chamber angle that is open by gonioscopic appearance.

This is a multicentric, crossover, double blind and prospective clinical study. The investigators will include patients with confirmed diagnosis of primary open-angle glaucoma or ocular hypertension, with target intraocular pressure (TIOP) within a range at which a patient is likely to remain stable or at which worsening of glaucoma will be slow enough that the risk of additional intervention is not justified.

Patients will be randomly divided into 2 groups, one of them treated with a known formulation of timolol 0.5%/brimonidine 0.2%/dorzolamide 2% (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with PRO-122 ophthalmic solution. Patients will receive 1 drop B.I.D. into the lower conjunctival sac of either formulations and were examined at days: 1, 15, 30, 45 and 61 after initiation of treatment. A phone call security at day 75 will be performed.

Primary efficacy outcome: To evaluate the efficacy of PRO-122 versus Krytantek Ofteno® instilled onto the ocular surface in subjects with primary open angle glaucoma (POAG) or ocular hypertension (HTO), to control and maintenance of the target intraocular pressure (TIOP).